It is well known that breast cancer cells expressing human epidermal growth factor receptor 2 (HER2) have a poor prognosis and survival associated with an increased rate of proliferation, invasion, angiogenesis, metastasis, and recurrence, as compared to HER2-negative tumors. Here, ERBB2 is linked to breast carcinoma.